RxDoctor Payments Data

Nancy Jones, APRN

Family · Charleston, SCNPI 1184003436

Payments from drug & device makers

$5,703in general payments, 2019–2025

Across 287 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821
  • Pfizer$560
  • AstraZeneca$538
  • Novo Nordisk$494
  • Lilly USA, LLC$372
  • Amgen$367
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,703 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,471
Medicare patients
277
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$29,996
JardianceEmpagliflozin25$26,781
TrulicityDulaglutide16$23,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$20,466
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$17,424
FarxigaDapagliflozin Propanediol27$13,990
EliquisApixaban14$11,900
Atorvastatin Calcium142$1,175
Levothyroxine Sodium95$1,016
Mirtazapine16$1,007
Amlodipine Besylate173$760
Rosuvastatin Calcium48$699
Albuterol Sulfate HfaAlbuterol Sulfate25$675
Losartan Potassium84$550
Pravastatin Sodium31$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$538$31,41446 claims
Novo NordiskOzempic$494$29,99624 claims
Boehringer IngelheimJardiance$276$26,78125 claims
Lilly USA, LLCTrulicity$372$23,28616 claims
GSKTrelegy Ellipta$349$20,46625 claims
PfizerEliquis$560$11,90014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →